|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2007-6-28
|
|
pubmed:abstractText |
While sirolimus (SRL) is thought to be a non-nephrotoxic agent, cyclosporine A (CsA) toxicity is a serious problem in kidney transplantation. We compared the effects of the two drugs on T-helper (Th) subsets in kidney transplant patients. We examined 24 first cadaver kidney recipients equally randomized to receive SRL/mycophenolate mofetil (MMF)/methylprednisolone (MP), or cyclosporine with either MMF or MP. The Th1 and Th2 subsets in peripheral blood were separated based on their production of interferon-gamma (INFgamma) or interleukin (IL)-4/IL-5. The lymphocytes were stimulated with phytohemoagglutinin or with allogenic CD3-depeted and irradiated antigen-presenting cells. Furthermore, the conversion potential of Th0 to Th1 was determined by measuring IL-12 and IL-18 levels after lipopolysaccharide challenge. When peripheral blood lymphocytes taken from SRL-treated patients were stimulated by phytohemoagglutinin, there were significantly lower INFgamma-producing cells compared with the lymphocytes taken from patients treated with CsA. The number of IL-4/IL-5-producing cells did not differ among the patient groups. Release of IL-12 but not IL-18 from peripheral lymphocytes following treatment with lipopolysaccharide was significantly lower in the SRL-treated patients. These results show that compared with CsA, SRL caused a significant decrease in the Th1 lymphocyte subset associated with a significant reduction of IL-12 release.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Anti-Inflammatory Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclosporine,
http://linkedlifedata.com/resource/pubmed/chemical/Immunosuppressive Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Interferon-gamma,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-12,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-18,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-4,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-5,
http://linkedlifedata.com/resource/pubmed/chemical/Methylprednisolone,
http://linkedlifedata.com/resource/pubmed/chemical/Mycophenolic Acid,
http://linkedlifedata.com/resource/pubmed/chemical/Sirolimus,
http://linkedlifedata.com/resource/pubmed/chemical/mycophenolate mofetil
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0085-2538
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
72
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
114-20
|
|
pubmed:dateRevised |
2008-11-21
|
|
pubmed:meshHeading |
pubmed-meshheading:17410097-Adult,
pubmed-meshheading:17410097-Anti-Inflammatory Agents,
pubmed-meshheading:17410097-Cells, Cultured,
pubmed-meshheading:17410097-Cyclosporine,
pubmed-meshheading:17410097-Female,
pubmed-meshheading:17410097-Gene Expression Regulation,
pubmed-meshheading:17410097-Humans,
pubmed-meshheading:17410097-Immunosuppressive Agents,
pubmed-meshheading:17410097-Interferon-gamma,
pubmed-meshheading:17410097-Interleukin-12,
pubmed-meshheading:17410097-Interleukin-18,
pubmed-meshheading:17410097-Interleukin-4,
pubmed-meshheading:17410097-Interleukin-5,
pubmed-meshheading:17410097-Kidney Transplantation,
pubmed-meshheading:17410097-Male,
pubmed-meshheading:17410097-Methylprednisolone,
pubmed-meshheading:17410097-Middle Aged,
pubmed-meshheading:17410097-Monocytes,
pubmed-meshheading:17410097-Mycophenolic Acid,
pubmed-meshheading:17410097-Sirolimus,
pubmed-meshheading:17410097-Th1 Cells,
pubmed-meshheading:17410097-Th2 Cells
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
The effect of sirolimus- or cyclosporine-based immunosuppression effects on T-cell subsets in vivo.
|
|
pubmed:affiliation |
Unit of Nephrology, Fondazione IRCCS Policlinico San Matteo, and University of Pavia, Italy. carmelo.libetta@unipv.it
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial
|
